Rong Biaoxue, Zhao Chongchong, Gao Wenlong, Yang Shuanying
Department of Oncology, The First Affiiated Hospital of Xi'an Medical University Xi'an, China.
Department of Neurology, Lanzhou University Second Hospital Lanzhou, China.
Int J Clin Exp Med. 2015 Sep 15;8(9):14701-17. eCollection 2015.
Many studies have investigated the efficacy of matrine combined with platinum-based doublet chemotherapy (PBDC) versus PBDC alone for treating advanced non-small cell lung cancer (NSCLC). This study is an analytic value of available evidence.
twenty-two studies reporting matrine combined with PBDC versus PBDC alone for treating advanced NSCLC were reviewed. Pooled odds ratios and hazard ratio with 95% confidence intervals were calculated using either the fixed effects model or random effects model.
The overall response rate (ORR) and disease control rate (DCR) of matrine combined with PBDC for treating NSCLC were significantly higher than those of PBDC alone, with 15.1% and 19.7% improvement, respectively (P < 0.00001). In addition, the mean survival time (MST) and quality of life (QOL) were improved after the treatment of matrine combined with PBDC (P < 0.00001). The main adverse effects found in this review were hematological reactions, nausea and vomiting. Matrine combined with PBDC had a lower incidence of adverse reactions compared with PBDC alone (P < 0.05).
Matrine combined with PBDC was associated with higher RR, DCR, and MST as well as superior QOL profiles compared with PBDC alone. Matrine combined with PBDC decrease the incidence of adverse reactions compared with PBDC alone.
许多研究探讨了苦参碱联合铂类双药化疗（PBDC）与单纯PBDC治疗晚期非小细胞肺癌（NSCLC）的疗效。本研究旨在分析现有证据的价值。
回顾了22项关于苦参碱联合PBDC与单纯PBDC治疗晚期NSCLC的研究。采用固定效应模型或随机效应模型计算合并比值比和风险比及其95%置信区间。
苦参碱联合PBDC治疗NSCLC的总缓解率（ORR）和疾病控制率（DCR）显著高于单纯PBDC，分别提高了15.1%和19.7%（P<0.00001）。此外，苦参碱联合PBDC治疗后患者的平均生存时间（MST）和生活质量（QOL）得到改善（P<0.00001）。本综述中发现的主要不良反应为血液学反应、恶心和呕吐。与单纯PBDC相比，苦参碱联合PBDC的不良反应发生率更低（P<0.05）。
与单纯PBDC相比，苦参碱联合PBDC具有更高的缓解率、疾病控制率和平均生存时间，以及更好的生活质量。与单纯PBDC相比，苦参碱联合PBDC降低了不良反应的发生率。
